🔗 Share this article Users Discontinuing Weight-Loss Medications Put On Weight Four Times Faster Than People Using Diet and Exercise Weight management involves long-term strategies. A recent study indicates that people who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who stop conventional lifestyle regimens. Research printed in a prominent health publication demonstrates that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month once they quit. "People using these drugs must be cognizant of the potential of quick rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb. Such speed of regain implies a reversion to original weight within about 18 months. Comparing Therapies The study, which examined 37 of trials involving thousands of patients, compared the results of GLP-1 agonists with older methods. The team emphasize that people who shed pounds through diet and exercise generally experience a slower creep back—approximately 0.1 kg a month—after stopping. Explaining the Fast Rebound Doctors propose the mechanism of the drugs explains the heightened regain. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls hunger. "Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher. "Withdrawal of this medication leads to appetite is no longer kept in check, making overeating a significant risk." An Ongoing Disease? Health authorities recommend the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications. Professionals say that, due to the likelihood of relapse, the therapy is often ongoing. This perspective is reinforced by drug manufacturers, who say that the results "highlight the chronic nature of excess weight," similar to managing diseases like high blood pressure. User Accounts Individuals who have come off the jabs explain a sudden resurgence of cravings. "It felt as if a trigger activating and I was suddenly ravenous," said one woman. The struggle is compounded if individuals have not developed permanent dietary or behavioural modifications during therapy. Widespread Interest Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow. Adoption is higher among women than males. The 40s and 50s age group shows the highest usage rates. A large proportion access the medications through private healthcare rather than public health services. Finally, researchers caution that while the jabs are potent tools for weight loss, they are not a standalone cure and long-term success hinges on integrated behavioural support.
Weight management involves long-term strategies. A recent study indicates that people who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who stop conventional lifestyle regimens. Research printed in a prominent health publication demonstrates that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month once they quit. "People using these drugs must be cognizant of the potential of quick rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb. Such speed of regain implies a reversion to original weight within about 18 months. Comparing Therapies The study, which examined 37 of trials involving thousands of patients, compared the results of GLP-1 agonists with older methods. The team emphasize that people who shed pounds through diet and exercise generally experience a slower creep back—approximately 0.1 kg a month—after stopping. Explaining the Fast Rebound Doctors propose the mechanism of the drugs explains the heightened regain. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls hunger. "Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher. "Withdrawal of this medication leads to appetite is no longer kept in check, making overeating a significant risk." An Ongoing Disease? Health authorities recommend the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications. Professionals say that, due to the likelihood of relapse, the therapy is often ongoing. This perspective is reinforced by drug manufacturers, who say that the results "highlight the chronic nature of excess weight," similar to managing diseases like high blood pressure. User Accounts Individuals who have come off the jabs explain a sudden resurgence of cravings. "It felt as if a trigger activating and I was suddenly ravenous," said one woman. The struggle is compounded if individuals have not developed permanent dietary or behavioural modifications during therapy. Widespread Interest Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow. Adoption is higher among women than males. The 40s and 50s age group shows the highest usage rates. A large proportion access the medications through private healthcare rather than public health services. Finally, researchers caution that while the jabs are potent tools for weight loss, they are not a standalone cure and long-term success hinges on integrated behavioural support.